A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours |
| |
Authors: | U Lassen L R Molife M Sorensen S-A Engelholm L Vidal R Sinha R T Penson P Buhl-Jensen E Crowley J Tjornelund P Knoblauch J S de Bono |
| |
Institution: | 1.Department of Oncology, University Hospital, Rigshospitalet, Copenhagen 2100, Denmark;2.Drug Development Unit, Institute of Cancer Research, The Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK;3.Department of Haematology/Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA;4.TopoTaget A/S, Symbion Science Park, Fruebjergvej 3, Copenhagen 2100, Denmark |
| |
Abstract: | Background: This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.Methods: Cohorts of three to six patients were treated with escalating doses of belinostat administered intravenously once daily, days 1–5 q21 days; on day 3, carboplatin (area under the curve (AUC) 5) and/or paclitaxel (175 mg m−2) were administered 2–3 h after the end of the belinostat infusion.Results: In all 23 patients received 600–1000 mg m−2 per day of belinostat with carboplatin and/or paclitaxel. No DLT was observed. The maximal administered dose of belinostat was 1000 mg m−2 per day for days 1–5, with paclitaxel (175 mg m−2) and carboplatin AUC 5 administered on day 3. Grade III/IV adverse events were (n; %): leucopenia (5; 22%), neutropenia (7; 30%), thrombocytopenia (3; 13%) anaemia (1; 4%), peripheral sensory neuropathy (2; 9%), fatigue (1; 4%), vomiting (1; 4%) and myalgia (1; 4%). The pharmacokinetics of belinostat, paclitaxel and carboplatin were unaltered by the concurrent administration. There were two partial responses (one rectal cancer and one pancreatic cancer). A third patient (mixed mullerian tumour of ovarian origin) showed a complete CA-125 response. In addition, six patients showed a stable disease lasting ⩾6 months.Conclusion: The combination was well tolerated, with no evidence of pharmacokinetic interaction. Further evaluation of anti-tumour activity is warranted. |
| |
Keywords: | HDAC belinostat carboplatin paclitaxel BelCaP |
|
|